These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29992442)

  • 1. A single-center retrospective study of onabotulinumtoxinA for treatment of 245 chronic migraine patients: survey results of a real-world experience.
    Yalinay Dikmen P; Kosak S; Ilgaz Aydinlar E; Sagduyu Kocaman A
    Acta Neurol Belg; 2018 Sep; 118(3):475-484. PubMed ID: 29992442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study.
    Domínguez C; Pozo-Rosich P; Torres-Ferrús M; Hernández-Beltrán N; Jurado-Cobo C; González-Oria C; Santos S; Monzón MJ; Latorre G; Álvaro LC; Gago A; Gallego M; Medrano V; Huerta M; García-Alhama J; Belvís R; Leira Y; Leira R
    Eur J Neurol; 2018 Feb; 25(2):411-416. PubMed ID: 29171146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine.
    Winner PK; Kabbouche M; Yonker M; Wangsadipura V; Lum A; Brin MF
    Headache; 2020 Mar; 60(3):564-575. PubMed ID: 32037549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short and Mid-Term Predictors of Response to OnabotulinumtoxinA: Real-Life Experience Observational Study.
    Alpuente A; Gallardo VJ; Torres-Ferrús M; Álvarez-Sabin J; Pozo-Rosich P
    Headache; 2020 Apr; 60(4):677-685. PubMed ID: 32086801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine.
    Cady RK; Schreiber CP; Porter JA; Blumenfeld AM; Farmer KU
    Headache; 2011 Jan; 51(1):21-32. PubMed ID: 21070228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential administration of peripheral nerve blocks and onabotulinumtoxinA for the treatment of chronic migraine and other headache disorders-A retrospective tolerability and safety study.
    Anderson CC; Iser CR; Hirte IL; Boddu S; Girardo ME; VanderPluym JH; Starling AJ
    Headache; 2024 Jun; 64(6):663-673. PubMed ID: 38700250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting.
    Santoro A; Fontana A; Miscio AM; Zarrelli MM; Copetti M; Leone MA
    Neurol Sci; 2017 Oct; 38(10):1779-1789. PubMed ID: 28726049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study.
    Stark C; Stark R; Limberg N; Rodrigues J; Cordato D; Schwartz R; Jukic R
    J Headache Pain; 2019 Jul; 20(1):81. PubMed ID: 31307383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
    Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
    J Headache Pain; 2019 Feb; 20(1):12. PubMed ID: 30709333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Onabotulinumtoxin-A treatment in Greek patients with chronic migraine.
    Vikelis M; Argyriou AA; Dermitzakis EV; Spingos KC; Mitsikostas DD
    J Headache Pain; 2016 Dec; 17(1):84. PubMed ID: 27640152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of OnabotulinumtoxinA on Aura Frequency and Severity in Patients With Hemiplegic Migraine: Case Series of 11 Patients.
    Chen TY; Garza I; Dodick DW; Robertson CE
    Headache; 2018 Jul; 58(7):973-985. PubMed ID: 29762872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
    Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
    J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe.
    Matharu M; Pascual J; Nilsson Remahl I; Straube A; Lum A; Davar G; Odom D; Bennett L; Proctor C; Gutierrez L; Andrews E; Johannes C
    Cephalalgia; 2017 Dec; 37(14):1384-1397. PubMed ID: 28758415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: Retrospective analysis of a US-based insurance claims database.
    Hepp Z; Rosen NL; Gillard PG; Varon SF; Mathew N; Dodick DW
    Cephalalgia; 2016 Aug; 36(9):862-74. PubMed ID: 26692400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OnabotulinumtoxinA in Chronic Migraine: A Profile of Its Use.
    Frampton JE
    CNS Drugs; 2020 Dec; 34(12):1287-1298. PubMed ID: 33314008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OnabotulinumtoxinA.
    Tepper D
    Headache; 2020 Nov; 60(10):2649-2650. PubMed ID: 33249584
    [No Abstract]   [Full Text] [Related]  

  • 18. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.
    Ahmed F; Gaul C; García-Moncó JC; Sommer K; Martelletti P;
    J Headache Pain; 2019 Mar; 20(1):26. PubMed ID: 30845917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.